EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

Dharmisha Chauhan iD, Cinzia Dello Russo iD, Jack Thompson iD, Dyfrig A Hughes iD, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding iD, Eleanor Lau und 13 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70659 ↗

Kurz gefasst

Leitlinie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Dharmisha Chauhan und 24 weiteren Autor:innen. Beteiligte Einrichtung: North Thames Genomic Medicine Service Alliance, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Irinotecan, Topoisomerase I Inhibitors, Pharmacogenomic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy. However, it is also used off‐label across a range of gastrointestinal malignancies and in rare malignancies such as glioblastoma and sarcomas. The pegylated formulation is licensed for use as combination therapy in adult patients with metastatic pancreatic adenocarcinoma. Irinotecan is hydrolysed to its active metabolite, SN‐38, which is predominantly inactivated by the enzyme uridine diphosphate glucuronosyltransferase UGT1A1. UGT1A1 is encoded by the gene UGT1A1 , which is polymorphically expressed, with allele frequencies varying across populations. Poor metabolizers carry two variants that reduce UGT1A1 enzyme expression or activity, leading to increased risk of irinotecan toxicity. Any patient who is about to be prescribed irinotecan for an epithelial malignancy should have pharmacogenetic testing, to identify clinically relevant UGT1A1 variants, where testing is available. Irinotecan dose should be reduced by 30% at Cycle 1 treatment in poor metabolizers for all indications, with doses titrated thereafter based on tolerability and neutrophil counts. The lack of evidence precludes us from making any recommendation for rare malignancies such as sarcomas. Our guideline is consistent with other international pharmacogenetics prescribing guidelines. This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk–benefit profile, ensuring that therapy is optimized to maximize benefits while minimizing potential harms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronosyltransferaseIrinotecanTopoisomerase I InhibitorsPharmacogenomic TestingCamptothecinHumansUGT1A1 EnzymeGenotypeUnited KingdomPharmacogenetics

Stichwörter der Autor:innen

UGT1A1diarrhoeairinotecanneutropeniapharmacogenetic testing

Substanzen

GlucuronosyltransferaseIrinotecanUGT1A1 EnzymeTopoisomerase I InhibitorsCamptothecin

Autor:innen und Institutionen

  • North Thames Genomic Medicine Service Alliance, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Royal Marsden NHS Foundation Trust, London, UK.
  • Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Department of Translational Medicine and Surgery, Section of Pharmacology, Università Cattolica del Sacro Cuore-Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
  • Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Centre for Health Economics and Medicines Evaluation, North Wales Medical School Bangor University, Bangor, UK.

ORCID-Profile: Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A Hughes, Sophie Harding, Munir Pirmohamed

Zitieren

APA

Chauhan, D., Dello Russo, C., Thompson, J., Hughes, D. A., Payne, K., Tsakiroglou, M., Ross, P., Chauhan, R., Jenkinson, S., Keen, J., Harding, S., Lau, E., Braun, M., Agarwal, R., Adams, R., Rolf, E., Al-Sheikhli, F., Mitchell, S., Hammond, R., …, & Pirmohamed, M. (2026). UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70659

Vancouver

Chauhan D, Dello Russo C, Thompson J, Hughes DA, Payne K, Tsakiroglou M, et al. UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70659

BibTeX
@article{Chauhan2026,
  author = {Chauhan, Dharmisha and Dello Russo, Cinzia and Thompson, Jack and Hughes, Dyfrig A and Payne, Katherine and Tsakiroglou, Maria and Ross, Paul and Chauhan, Rena and Jenkinson, Simon and Keen, Jessica and Harding, Sophie and Lau, Eleanor and Braun, Michael and Agarwal, Roshan and Adams, Richard and Rolf, Elisabeth and Al-Sheikhli, Farah and Mitchell, Sarah and Hammond, Ruth and Roberts, Rosie and Cairns, Lorna and Heggarty, Shirley and Graham, Janet and Mencel, Justin and Pirmohamed, Munir},
  title = {UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70659}
}
Kostenlos starten →